Search
Descriptor English: Dideoxyadenosine
Descriptor Spanish: Didesoxiadenosina
Descriptor didesoxiadenosina
Entry term(s) 2',3'-didesoxiadenosina
ddA (antiviral)
Scope note: Didesoxinucleosídico en el que el grupo 3'-hidroxi de la molécula de azúcar ha sido sustituido por un hidrógeno. Esta modificación impide la formación de los enlaces fosfodiéster que son necesarios para formar las cadenas de ácidos nucleicos. Este compuesto es un inhibidor de la replicación del VIH, que actúa como terminal de la cadena del ADN viral al unirse a la transcriptasa inversa. Su principal efecto secundario es la nefrotoxicidad. In vivo, la dideoxiadenosina se metaboliza rápidamente a DIDANOSINA (ddI) por la desaminación enzimática; ddI se convierte entonces en monofosfato de dideoxiinosina y, finalmente, en trifosfato de dideoxiadenosina, que es el metabolito putativo activo.
Descriptor Portuguese: Didesoxiadenosina
Descriptor French: Didéoxyadénosine
Entry term(s): 2',3' Dideoxyadenosine
2',3'-Dideoxyadenosine
ddA (Antiviral)
Tree number(s): D03.633.100.759.590.138.325.105
D13.570.230.229.105
D13.570.230.500.105
D13.570.583.138.325.105
RDF Unique Identifier: https://id.nlm.nih.gov/mesh/D016048
Scope note: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is an inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal side effect is nephrotoxicity. In vivo, dideoxyadenosine is rapidly metabolized to DIDANOSINE (ddI) by enzymatic deamination; ddI is then converted to dideoxyinosine monophosphate and ultimately to dideoxyadenosine triphosphate, the putative active metabolite.
Annotation: an antiviral; inhibits HIV replication
Allowable Qualifiers: AA analogs & derivatives
AD administration & dosage
AE adverse effects
AG agonists
AI antagonists & inhibitors
AN analysis
BL blood
CF cerebrospinal fluid
CH chemistry
CL classification
CS chemical synthesis
EC economics
HI history
IM immunology
IP isolation & purification
ME metabolism
PD pharmacology
PK pharmacokinetics
PO poisoning
RE radiation effects
SD supply & distribution
ST standards
TO toxicity
TU therapeutic use
UR urine
Pharm Action: Antimetabolites
Antiviral Agents
Registry Number: 4Q86AH641A
CAS Type 1 Name: Adenosine, 2',3'-dideoxy-
Previous Indexing: Deoxyadenosine/analogs & derivatives (1975-1989)
Dideoxynucleosides (1989)
Public MeSH Note: 90
History Note: 90
DeCS ID: 24602
Unique ID: D016048
Documents indexed in the Virtual Health Library (VHL): Click here to access the VHL documents
Date Established: 1990/01/01
Date of Entry: 1989/07/14
Revision Date: 2016/05/31
Dideoxyadenosine - Preferred
Concept UI M0024534
Scope note A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is an inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal side effect is nephrotoxicity. In vivo, dideoxyadenosine is rapidly metabolized to DIDANOSINE (ddI) by enzymatic deamination; ddI is then converted to dideoxyinosine monophosphate and ultimately to dideoxyadenosine triphosphate, the putative active metabolite.
Preferred term Dideoxyadenosine
Entry term(s) 2',3' Dideoxyadenosine
2',3'-Dideoxyadenosine
ddA (Antiviral)



We want your feedback on the new DeCS / MeSH website

We invite you to complete a survey that will take no more than 3 minutes.

Go to survey